Actionable Mutations in NSCLC: Expert Perspectives in Testing and Targeted Therapy

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.

Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.

A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.

Drs Fernando C. Santini and Hatim Hussain explain how they approach testing and treatment of patients with TRK fusion at diagnosis and progression in non–small cell lung cancer.

Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.